Treatment of pituitary dwarfism with methionyl human growth hormone in Japan.

Abstract

Sixty-two patients with pituitary dwarfism were treated with three different preparations of methionyl hGH (m-hGH) for 3 to 14 months. They were given 0.5 IU/kg/week intramuscularly. The growth rate during treatment with the three different preparations was the same for each and increased from 3.5 +/- 0.9 to 8.2 +/- 1.7 cm/year. A high incidence of hGH antibody formation was observed following the treatment, but the titer of antibody was decreased according to the purity of m-hGH preparations. At the end of 12 month treatment with a highly purified preparation (Somatonorm III), 76.2% of the patients had hGH antibody. However, the presence of antibodies did not affect the growth rate except in one patient. No clinical or laboratory side-effects were observed following the treatment with m-hGH. Thus, m-hGH was considered to be useful for the treatment of GH deficient children.

• Authors: K Takano, K Shizume, N Hizuka, A Okuno, T Umino, Y Kobayashi, S Kusano, H Nakajima, M Irie, I Hibi
• Journal: Endocrinologia japonica (Endocrinol Jpn) Vol. 33 Issue 5 Pg. 589-96 (Oct 1986) ISSN: 0013-7219 [Print] Japan
• PMID: 3830068 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Human Growth Hormone
• Growth Hormone

Topics

• Adolescent
• Antibody Formation
• Child
• Child, Preschool
• Dwarfism, Pituitary (drug therapy)
• Female
• Growth (drug effects)
• Growth Hormone (administration & dosage, analogs & derivatives, immunology, therapeutic use)
• Human Growth Hormone
• Humans
• Injections, Intramuscular
• Japan
• Male